Bio-Rad Laboratories, Inc. (BIO) Holdings Lifted by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 29.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 106,285 shares of the medical research company’s stock after acquiring an additional 24,149 shares during the period. Goldman Sachs Group Inc. owned about 0.36% of Bio-Rad Laboratories worth $24,053,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the business. Northwestern Mutual Investment Management Company LLC grew its holdings in shares of Bio-Rad Laboratories by 0.4% during the second quarter. Northwestern Mutual Investment Management Company LLC now owns 3,596 shares of the medical research company’s stock worth $514,000 after purchasing an additional 13 shares during the last quarter. World Asset Management Inc grew its holdings in shares of Bio-Rad Laboratories by 1.4% during the second quarter. World Asset Management Inc now owns 1,025 shares of the medical research company’s stock worth $232,000 after purchasing an additional 14 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Bio-Rad Laboratories by 1.8% during the second quarter. Teacher Retirement System of Texas now owns 1,666 shares of the medical research company’s stock worth $377,000 after purchasing an additional 29 shares during the last quarter. US Bancorp DE grew its holdings in shares of Bio-Rad Laboratories by 0.8% during the second quarter. US Bancorp DE now owns 4,224 shares of the medical research company’s stock worth $956,000 after purchasing an additional 34 shares during the last quarter. Finally, State of Wisconsin Investment Board grew its holdings in shares of Bio-Rad Laboratories by 1.0% during the second quarter. State of Wisconsin Investment Board now owns 4,187 shares of the medical research company’s stock worth $948,000 after purchasing an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 62.84% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.themarketsdaily.com/2017/10/13/bio-rad-laboratories-inc-bio-holdings-lifted-by-goldman-sachs-group-inc.html.

Several analysts have recently weighed in on the company. Zacks Investment Research cut Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Deutsche Bank AG upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating and reduced their target price for the company from $220.00 to $195.00 in a report on Wednesday, June 28th. TheStreet cut Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday, August 3rd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $275.00 target price on shares of Bio-Rad Laboratories in a report on Friday, July 14th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $260.00.

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) opened at 223.89 on Friday. The company has a market capitalization of $6.64 billion, a PE ratio of 442.47 and a beta of 0.91. Bio-Rad Laboratories, Inc. has a one year low of $154.89 and a one year high of $242.79. The company has a 50-day moving average price of $222.39 and a 200 day moving average price of $220.85.

In other news, EVP Michael Crowley sold 700 shares of Bio-Rad Laboratories stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $215.91, for a total value of $151,137.00. Following the sale, the executive vice president now directly owns 2,060 shares in the company, valued at approximately $444,774.60. The sale was disclosed in a filing with the SEC, which is available through this link. 28.29% of the stock is currently owned by company insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply